Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Trial Profile

Pilot Study of recMAGE-A3 + AS15 ASCI as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation.

Completed
Phase of Trial: Phase I

Latest Information Update: 27 Dec 2016

At a glance

  • Drugs Zastumotide (Primary) ; AS15
  • Indications Multiple myeloma
  • Focus Adverse reactions
  • Most Recent Events

    • 31 Oct 2016 Status changed from active, no longer recruiting to completed.
    • 02 May 2015 Planned End Date changed from 1 Oct 2014 to 1 May 2018 as reported by ClinicalTrials.gov record.
    • 02 May 2015 Planned primary completion date changed from 1 Aug 2014 to 1 Jul 2014 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top